Literature DB >> 9736564

In vitro pharmacodynamic studies of L-749,345 in comparison with imipenem and ceftriaxone against gram-positive and gram-negative bacteria.

I Odenholt1, E Löwdin, O Cars.   

Abstract

L-749,345 is a new parenteral carbapenem with a very long half-life similar to that of ceftriaxone. The aim of the present study was to investigate different pharmacodynamic parameters of L-749,345 in comparison with those of ceftriaxone and imipenem. The following studies were performed: (i) comparative studies of the MICs of L-749, 345, imipenem, and ceftriaxone for 70 strains of gram-positive and gram-negative bacteria; (ii) comparative studies of the rate of killing of gram-positive and gram-negative bacteria by L-749,345, imipenem, and ceftriaxone; (iii) studies of the postantibiotic effects of L-749,345, imipenem, and ceftriaxone; and (iv) studies of the postantibiotic sub-MIC effects of L-749,345, imipenem, and ceftriaxone. Significantly lower MICs of L-749,345 compared with those of ceftriaxone were found for all gram-negative organisms except Haemophilus influenzae. The MICs of L-749,345 were similar to those of imipenem for all organisms except Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus, for which the MICs of L-749,345 were higher. A concentration-dependent killing of methicillin-resistant S. aureus but not methicillin-susceptible strains was noted for both L-749,345 and imipenem. All three of the investigated drugs exhibited a postantibiotic effect against the gram-positive strains but exhibited no postantibiotic effect against the gram-negative strains.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9736564      PMCID: PMC105834     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Comparative in vitro pharmacodynamics of BO-2727, meropenem and imipenem against Gram-positive and Gram-negative bacteria.

Authors:  Inga Odenholt; Elisabeth Löwdin; Otto Cars
Journal:  Clin Microbiol Infect       Date:  1997-02       Impact factor: 8.067

2.  Effects of supra- and sub-MIC benzylpenicillin concentrations on group A beta-haemolytic streptococci during the postantibiotic phase in vivo.

Authors:  I Odenholt; S E Holm; O Cars
Journal:  J Antimicrob Chemother       Date:  1990-08       Impact factor: 5.790

3.  Effects of benzylpenicillin on Streptococcus pyogenes during the postantibiotic phase in vitro.

Authors:  I Odenholt; S E Holm; O Cars
Journal:  J Antimicrob Chemother       Date:  1989-08       Impact factor: 5.790

4.  Beta-lactamase stability of imipenem.

Authors:  R Labia; A Morand; M Guionie
Journal:  J Antimicrob Chemother       Date:  1986-12       Impact factor: 5.790

5.  Postantibiotic suppression of bacterial growth.

Authors:  R W Bundtzen; A U Gerber; D L Cohn; W A Craig
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb

6.  The postantibiotic effect of meropenem and imipenem on selected bacteria.

Authors:  H L Nadler; D H Pitkin; W Sheikh
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

7.  In-vitro studies of meropenem.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

8.  Pharmacodynamic effects of subinhibitory concentrations of beta-lactam antibiotics in vitro.

Authors:  I Odenholt-Tornqvist; E Löwdin; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

9.  Kinetics of antimicrobial activity.

Authors:  B Vogelman; W A Craig
Journal:  J Pediatr       Date:  1986-05       Impact factor: 4.406

Review 10.  The carbapenems: new broad spectrum beta-lactam antibiotics.

Authors:  R C Moellering; G M Eliopoulos; D E Sentochnik
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

View more
  15 in total

1.  Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents.

Authors:  Glenn A Pankuch; Todd A Davies; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

2.  In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 3.  Comparative pharmacokinetics of the carbapenems: clinical implications.

Authors:  J W Mouton; D J Touzw; A M Horrevorts; A A Vinks
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

4.  Tissue penetration by ertapenem, a parenteral carbapenem administered once daily, in suction-induced skin blister fluid in healthy young volunteers.

Authors:  T Laethem; I De Lepeleire; J McCrea; J Zhang; A Majumdar; D Musson; D Rogers; S Li; M Guillaume; A Parneix-Spake; P Deutsch
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

5.  In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds.

Authors:  Dianne B Hoellman; Linda M Kelly; Kim Credito; Lauren Anthony; Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

6.  Pharmacokinetics and tolerability of single-dose intravenous ertapenem in infants, children, and adolescents.

Authors:  Susan M Abdel-Rahman; Gregory L Kearns; Santiago Topelberg; Richard F Jacobs; Goutam C Mistry; Anup Majumdar; Yang Xu; John A Wagner; Chester J Kitchen; Michelle Groff; Gary Herman; Jeffrey L Blumer
Journal:  Pediatr Infect Dis J       Date:  2010-12       Impact factor: 2.129

Review 7.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  Postantibiotic effect of ceftaroline against gram-positive organisms.

Authors:  G A Pankuch; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-10       Impact factor: 5.191

Review 9.  Comparative review of the carbapenems.

Authors:  George G Zhanel; Ryan Wiebe; Leanne Dilay; Kristjan Thomson; Ethan Rubinstein; Daryl J Hoban; Ayman M Noreddin; James A Karlowsky
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  Postantibiotic, postantibiotic sub-MIC, and subinhibitory effects of PGE-9509924, ciprofloxacin, and levofloxacin.

Authors:  Inga Odenholt; Elisabeth Löwdin; Otto Cars
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.